BUY Karur Vysya Bank

Sustains strong delivery on RoA

BFSI - Banks > Result Update > October 17, 2023

KVB continued its upward RoA/RoE drift in 2Q as well, posting a robust 1.6%/17%, despite softening of NIM (4.1% in Q2FY24 vs 4.2% in Q1FY24), mainly led by contained LLP. The bank reported strong credit (gross) growth, at 16% YoY/5% QoQ for Q2FY24, while focus remains on delivering higher profitability as against chasing growth. Asset quality continued to improve, with fall in GNPA ratio by 26bps QoQ to 1.7% and in NNPA to a low 0.5%, as the bank's PCR increased to 73%.

We expect KVB to register its decadal best RoA/RoE, at 1.5%/16% over FY24-26E, led by healthy NIM/fees and contained LLP. We retain BUY on KVB with revised TP of Rs185/share (vs Rs178), rolling forward to 1.2x Sep-25E ABV. KVB remains our preferred pick in the small-cap banking space, given its superior returns/capital ratios and Management credibility.

Karur Vysya Bank: Financial Snapshot (Standalone)										
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E					
Net profit	6,733	11,061	15,028	17,361	20,029					
Loan growth (%)	8.5	15.5	15.4	15.7	16.0					
NII growth (%)	15.1	23.3	10.7	13.3	14.9					
NIM (%)	3.7	4.1	4.0	3.9	3.9					
PPOP growth (%)	26.2	51.9	6.8	14.4	19.4					
Adj. EPS (Rs)	8.4	13.8	18.7	21.6	25.0					
Adj. EPS growth (%)	87.2	63.9	35.8	15.5	15.4					
Adj. BV (INR)	83.2	102.7	119.7	138.3	159.3					
Adj. BVPS growth (%)	17.2	23.4	16.6	15.5	15.2					
RoA (%)	0.9	1.3	1.5	1.5	1.5					
RoE (%)	9.3	13.7	16.3	16.3	16.4					
P/E (x)	16.4	10.0	7.3	6.4	5.5					
P/ABV (x)	1.6	1.3	1.1	1.0	0.9					

Source: Company, Emkay Research

Moderate credit growth, while margin slips due to rising CoF

KVB reported a healthy credit (gross) growth of 16% YoY/5% QoQ, primarily led by better CRB and Retail portfolio growth (mainly LAP/mortgage and gold loans). Bank's stance to let go of the low-yield corporate portfolio is still intact, as is evident from its portfolio's moderate & opportunistic growth. However, deposit growth was relatively modest at 13% YoY, leading to higher LDR of 84%. But CASA ratio declined by 63bps to 32.3% — a phenomenon seen across banks due to cannibalization. NIM contracted by 12bps QoQ to 4.1% (due to rising CoF), as guided by Management, although the pace of contraction should ease from hereon.

NPAs continue to trend down

GNPA/NNPA further improved to 1.7%/0.5% (vs 2.0%/0.6% in Q1FY24) owing to low slippages and better recovery trends. The restructured book also contracted, to 1.2% of loans in Q2FY24 vs. 1.4% in Q1FY24. The bank expects gross slippages of ~1% and net slippages to be negative in FY24 as well; this should lead to further improvement in the GNPA ratio. The bank now carries a healthy PCR, at 73% (technical PCR at 94%), while it has guided for LLP below 1% in FY24E vs. 150bps in FY23, which should help the bank deliver a strong RoA despite the pressure on margin.

We retain BUY; KVB remains our most preferred pick in small cap-banking space

KVB remains our top pick in the small-cap banking space, given its superior return ratios (RoA/RoE of 1.5/16% over FY24-26E), healthy capital ratios and Management's credibility. We retain our BUY rating, with a revised TP of Rs185/share (earlier Rs178/share), rolling forward on 1.2x its Sep-25E ABV. **Key risks:** Slower-than-expected growth, faster decline in CASA leading to cost pressure, and resurgence of NPAs in the retail/SME sector due to macro dislocation.



Ticker

TARGET PRICE (Rs): 185

Target Price – 12M	Sep-24
Change in TP (%)	3.9
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	34.4
CMP (16-Oct-23) (Rs)	137.6

Stock Data

Stock Bata	Ticker
52-week High (Rs)	144
52-week Low (Rs)	83
Shares outstanding (mn)	799.2
Market-cap (Rs bn)	110
Market-cap (USD mn)	1,320
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	270.8
ADTV-3M (USD mn)	3.3
Free float (%)	97.0
Nifty-50	19,732
INR/USD	83.3
Shareholding, Jun-23	
Promoters (%)	2.2
FPIs/MFs (%)	17.9/32.1

Price Performance									
(%) 1M 3M 12M									
Absolute	3.5	11.0	63.8						
Rel. to Nifty 5.9 10.0 42.7									





Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275


Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/18/2023 11:34 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Story in Charts

Exhibit 1: Deposit/Credit growth trajectory continues...




Source: Company, Emkay Research

Exhibit 3: CASA ratio saw a mild dip owing to cannibalization




Source: Company, Emkay Research

Exhibit 5: Better recovery trends and moderate slippages led to improved asset quality...




Source: Company, Emkay Research

Exhibit 7: We expect return ratios to showcase steady growth, led by healthy NIM and contained LLP




Portfolio Breakup (%)




Source: Company, Emkay Research

Exhibit 4: NIM contracts due to rising CoF, but is expected to ease going forward



Source: Company, Emkay Research

Exhibit 6: ...and an overall healthy fall in segmental NPAs as well



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 1.0x its one-year fwd ABV



Source: Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions com use and downloaded at 10/18/2023 11:34 AM Emkay Résearch is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 2: ...with a well-balanced portfolio mix

Source: Company, Emkay Research

Exhibit 9: Actuals vs Estimates (Q2FY24)

(Rs mn) Actu	Actuals	Estimates		Variati	on	Comments	
	Actuals	Emkay	Consensus	Emkay	Consensus	Comments	
Net income	12,543	12,540	11,252	0%	11%	In-line NII and other income	
PPOP	6,379	6,384	5,856	0%	9%	In-line PPoP growth	
РАТ	3,785	3,699	3,269	2% 16%		In-line PPOP and lower LLP led to the beat	

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	FY23A	FY24E	YoY (%)
Interest Earned	15,795	16,952	17,683	18,829	19,971	26.4	6.1	65,166	81,293	25
Interest Exp	7,581	8,062	8,757	9,858	10,817	42.7	9.7	31,677	44,237	40
Net Interest Income	8,214	8,890	8,926	8,971	9,154	11.4	2.0	33,488	37,056	11
Global NIMs (reported)	4.10	4.36	4.37	4.19	4.07	-3bps	-12bps	4.14	4.00	-14bps
Non-interest Income	2,416	3,175	4,008	3,332	3,389	40.3	1.7	11,589	14,250	23
Operating Expenses	4,906	5,175	5,543	5,818	6,164	25.6	5.9	20,320	24,870	22
Pre Provisioning Profit	5,723	6,890	7,391	6,484	6,379	11.5	-1.6	24,758	26,436	7
Provision & Contingencies	2,272	3,641	2,930	1,594	1,264	-44.4	-20.7	10,389	6,354	-39
PBT	3,451	3,249	4,460	4,890	5,115	48.2	4.6	14,369	20,083	40
Income Tax Expense (Gain)	949	356	1,082	1,304	1,331	40.2	2.1	3,308	5,055	53
Net Profit/(Loss)	2,502	2,893	3,378	3,586	3,785	51.2	5.5	11,061	15,028	36
Gross NPA (%)	3.97	2.66	2.27	1.99	1.73	-224bps	-26bps	2.27	1.68	-60bps
Net NPA (%)	1.36	0.89	0.74	0.59	0.47	-89bps	-13bps	0.74	0.51	-23bps
Deposits (Rs bn)	734	762	766	807	831	13.2	2.9	766	874	14
Net Advances (Rs bn)	602	617	631	660	695	15.5	5.4	631	729	15

Source: Company, Emkay Research

Exhibit 11: Revision in Estimates

Y/E Mar (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	51,203	51,306	0.2%	57,661	58,441	1.4%	66,389	67,649	1.9%
PPOP	26,440	26,436	0.0%	29,529	30,243	2.4%	35,063	36,121	3.0%
PAT	14,943	15,028	0.6%	17,135	17,361	1.3%	19,629	20,029	2.0%
EPS (Rs)	18.6	18.7	0.5%	21.4	21.6	1.2%	24.5	25.0	2.0%
BV (Rs)	123.2	123.2	0.0%	141.7	141.8	0.1%	163.2	163.4	0.1%

Source: Company, Emkay Research

Exhibit 12: Key assumptions	6			
	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	15.5	15.4	15.7	16.0
Deposit Growth (%)	11.9	14.0	14.8	15.4
NIM (%)	4.1	4.0	3.9	3.9
GNPA (%)	2.3	1.7	1.5	1.5
Credit Cost (%)	1.1	0.9	0.9	1.0

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 10/18/2023 11:34 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit	13:	Key	Ratios	and	Trends
---------	-----	-----	--------	-----	--------

Karur Vysya Bank (KVB IN)

	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Loans (Rs mn)	5,13,813	5,32,270	5,46,612	5,75,590	6,01,614	6,17,090	6,31,341	6,59,730	6,95,074
Growth YoY (%)	7.4	7.5	8.5	15.2	17.1	15.9	15.5	14.6	15.5
Growth QoQ (%)	2.8	3.6	2.7	5.3	4.5	2.6	2.3	4.5	5.4
Liability Profile & Margins									
Deposits (Rs mn)	6,54,101	6,68,710	6,84,860	7,11,680	7,33,980	7,61,750	7,66,376	8,07,150	8,30,685
Growth YoY (%)	7.0	7.7	8.2	10.5	12.2	13.9	11.9	13.4	13.2
Growth QoQ (%)	1.6	2.2	2.4	3.9	3.1	3.8	0.6	5.3	2.9
CASA (%)	35.4	36.1	34.9	36.4	35.3	33.9	33.2	32.9	32.3
CA (%)	10.7	11.1	10.1	11.2	10.9	10.3	9.7	10.1	9.8
SA (%)	24.8	25.0	24.8	25.2	24.4	23.5	23.5	22.8	22.5
Branches (no. of)	781	781	789	789	792	792	799	808	824
NIM (%)	3.74	3.68	3.82	3.85	4.10	4.36	4.37	4.19	4.07
Asset Quality (%)									
GNPA	7.4	7.0	6.0	5.2	4.0	2.7	2.3	2.0	1.7
NNPA	3.0	2.6	2.3	1.9	1.4	0.9	0.7	0.6	0.5
PCR	61.3	65.1	63.3	64.7	66.7	67.1	67.9	70.7	73.5
Capital Adequacy (%)									
CRAR	18.8	18.8	19.5	19.2	18.3	17.9	18.6	17.7	16.8
Tier I	16.8	16.8	17.5	17.3	16.4	16.0	16.8	16.0	15.2
ROE Decomposition (%)									
NII	3.6	3.6	3.6	3.6	3.9	4.1	4.0	3.9	3.8
Other Income	0.9	1.0	1.0	1.0	1.1	1.4	1.8	1.4	1.4
Opex	2.5	2.5	2.4	2.3	2.3	2.4	2.5	2.5	2.6
РРОР	2.0	2.1	2.2	2.3	2.7	3.1	3.3	2.8	2.6
Provisioning cost	0.9	0.8	0.7	0.8	1.1	1.7	1.3	0.7	0.5
PBT	1.1	1.3	1.5	1.6	1.6	1.5	2.0	2.1	2.1
ROA	0.9	1.0	1.1	1.1	1.2	1.3	1.5	1.6	1.6
ROE	9.3	10.2	11.4	11.9	12.7	14.3	16.1	16.4	16.7

Source: Company, Emkay Research

Karur Vysya Bank: Standalone Financials and Valuations

Profit & Loss

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	55,877	65,166	81,293	90,402	1,00,936
Interest Expense	28,723	31,677	44,237	48,426	52,712
Net interest income	27,154	33,488	37,056	41,976	48,224
NII growth (%)	15.1	23.3	10.7	13.3	14.9
Other income	7,691	11,589	14,250	16,466	19,425
Total Income	34,844	45,077	51,306	58,441	67,649
Operating expenses	18,542	20,320	24,870	28,198	31,528
РРОР	16,302	24,758	26,436	30,243	36,121
PPOP growth (%)	26.2	51.9	6.8	14.4	19.4
Core PPOP	16,804	24,466	24,436	27,743	32,621
Provisions & contingencies	6,993	10,389	6,354	7,043	9,355
РВТ	9,309	14,369	20,083	23,200	26,766
Extraordinary items	0	0	0	0	0
Tax expense	2,577	3,308	5,055	5,839	6,737
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	6,733	11,061	15,028	17,361	20,029
PAT growth (%)	87.3	64.3	35.9	15.5	15.4
Adjusted PAT	6,733	11,061	15,028	17,361	20,029
Diluted EPS (Rs)	8.4	0.0	0.0	0.0	0.0
Diluted EPS growth (%)	86.9	(100.0)	0.0	0.0	0.0
DPS (Rs)	1.6	2.0	2.5	3.0	3.4
Dividend payout (%)	19.0	14.5	13.4	13.9	13.6
Effective tax rate (%)	27.7	23.0	25.2	25.2	25.2
Net interest margins (%)	3.7	4.1	4.0	3.9	3.9
Cost-income ratio (%)	53.2	45.1	48.5	48.2	46.6
Shares outstanding (mn)	800.0	802.1	802.7	802.7	802.7

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	1,600	1,604	1,605	1,605	1,605
Reserves & surplus	74,362	84,236	97,258	1,12,210	1,29,511
Net worth	75,962	85,841	98,863	1,13,816	1,31,116
Deposits	6,84,860	7,66,376	8,73,727	10,02,807	11,56,852
Borrowings	13,391	14,320	16,683	19,636	23,327
Interest bearing liab.	6,98,250	7,80,696	8,90,409	10,22,443	11,80,179
Other liabilities & prov.	26,500	35,258	50,682	65,260	76,951
Total liabilities & equity	8,00,712	9,01,794	10,39,955	12,01,519	13,88,246
Net advances	5,46,612	6,31,341	7,28,769	8,42,939	9,77,919
Investments	1,72,161	1,88,083	2,13,149	2,43,697	2,75,150
Cash, other balances	49,262	46,951	53,425	61,347	70,811
Interest earning assets	7,68,034	8,66,376	9,95,343	11,47,983	13,23,880
Fixed assets	4,785	4,350	6,992	7,804	8,711
Other assets	27,894	31,068	37,620	45,732	55,655
Total assets	8,00,713	9,01,794	10,39,955	12,01,519	13,88,246
BVPS (Rs)	95.0	107.0	123.2	141.8	163.4
Adj. BVPS (INR)	83.2	102.7	119.7	138.3	159.3
Gross advances	5,68,315	6,41,241	7,37,428	8,51,729	9,88,006
Credit to deposit (%)	79.8	82.4	83.4	84.1	84.5
CASA ratio (%)	34.9	33.2	32.0	33.1	35.0
Cost of deposits (%)	4.2	4.2	5.2	5.0	4.8
Loans-to-Assets (%)	68.3	70.0	70.1	70.2	70.4
Net advances growth (%)	8.5	15.5	15.4	15.7	16.0
Deposit growth (%)	8.2	11.9	14.0	14.8	15.4
Book value growth (%)	9.0	12.7	15.1	15.1	15.2

Source: Company, Emkay Research

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Asset quality					
Gross NPLs	34,310.5	14,581.6	12,369.3	12,556.7	14,409.2
Net NPLs	12,607.9	4,681.5	3,710.8	3,767.0	4,322.8
GNPA ratio (%)	6.0	2.3	1.7	1.5	1.5
NNPA ratio (%)	2.3	0.7	0.5	0.4	0.4
Provision coverage (%)	63.3	67.9	70.0	70.0	70.0
Gross slippages	8,427.3	4,792.4	7,374.3	9,369.0	12,350.1
Gross slippage ratio (%)	1.6	0.8	1.0	1.1	1.3
LLP ratio (%)	1.3	1.1	0.9	0.9	1.0
NNPA to networth (%)	16.2	5.3	3.6	3.2	3.2
Capital adequacy					
Total CAR (%)	19.5	18.6	18.5	18.4	18.2
Tier-1 (%)	17.5	16.8	17.0	17.0	17.0
CET-1 (%)	17.5	16.9	17.1	17.1	17.1
RWA-to-Total Assets (%)	52.0	54.4	54.0	54.0	54.0
Miscellaneous					
Total income growth (%)	(0.5)	20.7	24.5	11.9	12.6
Opex growth (%)	(6.7)	9.6	22.4	13.4	11.8
Core PPOP growth (%)	56.4	45.6	(0.1)	13.5	17.6
PPOP margin (%)	25.6	32.3	27.7	28.3	30.0
PAT/PPOP (%)	41.3	44.7	56.8	57.4	55.5
LLP-to-Core PPOP (%)	43.1	27.9	24.8	26.1	29.0
Yield on advances (%)	8.9	9.2	10.0	9.6	9.3
Cost of funds (%)	4.2	4.3	5.3	5.1	4.8

Source: Company, Emkay Research

Valuations and key Ratios FY22 FY26E Y/E Mar **FY23** FY24E FY25E P/E (x) 16.4 10.0 7.3 6.4 5.5 P/B (x) 1.7 1.3 1.0 0.9 1.1 P/ABV (x) 1.6 1.3 1.1 1.0 0.9 P/PPOP (x) 6.7 4.4 4.1 3.6 3.0 Dividend yield (%) 1.2 1.5 1.8 2.2 2.5 DuPont-RoE split (%) 3.7 NII/avg assets 3.5 3.9 3.8 3.7 Other income 1.0 1.4 1.5 1.5 1.5 Fee income 0.8 0.9 0.9 0.9 0.9 Opex 2.4 2.4 2.6 2.5 2.4 PPOP 2.9 2.8 2.1 2.7 2.7 Core PPOP 2.2 2.9 2.5 2.5 2.5 Provisions 0.9 1.2 0.7 0.6 0.7 0.4 0.5 Tax expense 0.3 0.5 0.5 RoA (%) 0.9 1.3 1.5 1.5 1.5 Leverage ratio (x) 10.6 10.5 10.5 10.5 10.6 RoE (%) 9.3 13.7 16.3 16.3 16.4 **Quarterly data** 02FY24 Rs mn, Y/E Mar 02EV23 03EV23 04EV23 01EV24

KS IIII, T/ L Pidi	Q21125	Q31123	Q41125	Q11124	Q21124
NII	8,214	8,890	8,926	8,971	9,154
NIM (%)	4.1	4.4	4.4	4.2	4.1
PPOP	5,723	6,890	7,391	6,484	6,379
PAT	2,502	2,893	3,378	3,586	3,785
EPS (Rs)	3.13	3.62	4.21	4.48	4.73


Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 10/18/2023 11:34 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
17-Jul-23	127	178	Buy	Anand Dama
14-Jun-23	115	165	Buy	Anand Dama
16-May-23	98	155	Buy	Anand Dama
09-Mar-23	104	155	Buy	Anand Dama
23-Jan-23	109	155	Buy	Anand Dama
22-Oct-22	91	125	Buy	Anand Dama
03-Oct-22	79	95	Buy	Anand Dama
30-Aug-22	69	95	Buy	Anand Dama
26-Jul-22	59	78	Buy	Anand Dama
22-May-22	45	72	Buy	Anand Dama
01-Feb-22	51	72	Buy	Anand Dama
11-Nov-21	58	72	Buy	Anand Dama
05-Aug-21	47	62	Buy	Anand Dama
01-Jun-21	56	62	Hold	Anand Dama
12-Feb-21	55	62	Hold	Anand Dama
20-Jan-21	46	53	Hold	Anand Dama
03-Nov-20	32	33	Hold	Anand Dama

RECOMMENDATION HISTORY - TREND





Source: Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay@whitemarguesolutions com use and downloaded at 10/18/2023 11:34 Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singa analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. on Distribution. In Singapore, this research report or research

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of October 17, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of October 17, 2023 EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject
- 5 company at the end of the month immediately preceding the October 17, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 10/18/2023 11:34 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.